RARE PHOTOS: 3 - The Real Truth

How high-cost Switzerland stayed a manufacturing powerhouse in the offshore era

What is the lesson of Swiss Fortune 500 companies—such as dsm-firmenich—for the rest of Europe, and the world?

Fortune · Oct 2, 2025

Pharma's Direct-To-Patient Wave Hits Novartis Next

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.

Benzinga · Sep 29, 2025

The Nations And Firms Threatened By Trump's Pharma Tariffs

Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.

International Business Times · Sep 26, 2025

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK · Sep 16, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.

Benzinga · Sep 15, 2025

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from domestic manufacturing to cutting-edge RD. For investors, it's a rare opportunity: major drugmakers are expanding fast, and some could be poised to…

Benzinga · Sep 9, 2025

Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were lower, with the Nasdaq Composite falling around 0.1% on Tuesday.

Benzinga · Sep 9, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver

Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback

MarketBeat · Sep 9, 2025

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

Benzinga · Sep 9, 2025

Scotland becomes first in UK to screen babies for 'devastating' rare condition

Scotland is to become the first part of the UK to routinely screen newborn babies for a 'devastating' rare medical condition ...

The National (Scotland) · Sep 5, 2025